Phospholamban antisense oligonucleotides improve cardiac function in murine cardiomyopathy
Heart failure is a major cause of morbidity and mortality worldwide. Here the authors show that subcutaneous administration of antisense oligonucleotides targeting PLN is an effective strategy in preclinical models of genetic cardiomyopathy and ischemia-driven heart failure.
Bibliographic Details
Main Authors: |
Niels Grote Beverborg,
Daniela Später,
Ralph Knöll,
Alejandro Hidalgo,
Steve T. Yeh,
Zaher Elbeck,
Herman H. W. Silljé,
Tim R. Eijgenraam,
Humam Siga,
Magdalena Zurek,
Malin Palmér,
Susanne Pehrsson,
Tamsin Albery,
Nils Bomer,
Martijn F. Hoes,
Cornelis J. Boogerd,
Michael Frisk,
Eva van Rooij,
Sagar Damle,
William E. Louch,
Qing-Dong Wang,
Regina Fritsche-Danielson,
Kenneth R. Chien,
Kenny M. Hansson,
Adam E. Mullick,
Rudolf A. de Boer,
Peter van der Meer |
Format: | Article
|
Language: | English |
Published: |
Nature Publishing Group
2021-08-01
|
Series: | Nature Communications
|
Online Access: | https://doi.org/10.1038/s41467-021-25439-0
|